Guidelines help safely perform cosmetic procedures on vitiligo patients to avoid new skin lesions.
December 2025 in “Cosmoderma” Systemic corticosteroids help manage vitiligo by slowing progression and aiding repigmentation.
November 2025 in “Clinics and Practice” Red ink tattoos can cause severe skin reactions and complications, especially in those with autoimmune tendencies.
November 2025 in “Journal of Investigative Dermatology” TEC kinases may help cause inflammation in vitiligo and could be targeted for treatment.
November 2025 in “Journal of Investigative Dermatology” Combining MMP-9 and JAK inhibitors can effectively prevent skin depigmentation in vitiligo.
October 2025 in “Journal of the European Academy of Dermatology and Venereology” People often have negative attitudes towards facial skin conditions, with vitiligo seen most positively and psoriasis viewed most negatively.
September 2025 in “Acta Dermato Venereologica” Baricitinib can help improve hair loss and skin color issues in people with Down syndrome.
September 2025 in “Journal of the American Academy of Dermatology” Vitiligo may be linked to stopping finasteride.
August 2025 in “Libyan Medical Journal” People with vitiligo or alopecia areata have higher anxiety and depression than healthy people.
August 2025 in “Dermatology and Therapy” Vitiligo is often linked with thyroid disease and other autoimmune conditions.
June 2025 in “Academic Medical Journal” Vitiligo treatments are improving but relapses are common.
May 2025 in “Journal of the Egyptian Womenʼs Dermatologic Society” Hair follicles in nonsegmental vitiligo are better protected from immune attacks than in alopecia areata.
April 2025 in “Journal of Dermatology for Physician Assistants” Vitiligo and alopecia should be covered by Medicaid and TRICARE as medical, not cosmetic, conditions.
January 2025 in “Frontiers in Medicine” Hair follicles are key to treating vitiligo and alopecia areata, but challenges exist.
January 2025 in “The Egyptian Journal of Hospital Medicine” Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.
January 2025 in “Plastic Surgery and Reconstructive Medicine” Plasmatherapy improves immune status in vitiligo patients, especially those with segmental vitiligo.
January 2025 in “Tanzania journal of health research/Tanzania Journal of Health Research” Autologous mini-punch grafting can effectively repigment stable vitiligo, but has some risks and limitations.
December 2024 in “Journal of Clinical Medicine of Kazakhstan” Vitiligo treatments include JAK inhibitors, UVB phototherapy, and dietary changes, with emotional support being important.
December 2024 in “International Journal of Dermatology” JAK inhibitors may help treat both alopecia areata and vitiligo, but more research is needed.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Patients with anxiety or depression report more severe alopecia areata.
November 2024 in “Journal of the European Academy of Dermatology and Venereology” More effective treatments are needed for alopecia areata, hidradenitis suppurativa, and vitiligo.
September 2024 in “Pigment International” Vitiligo is now seen as a systemic disease with promising new treatments and may offer protection against some diseases.
August 2024 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib and narrowband UVB effectively treated a child's vitiligo and alopecia areata.
July 2024 in “International Journal of Dermatology Venereology and Leprosy Sciences” Surgical treatments for vitiligo are safe and effective for some patients.
April 2024 in “The Indonesian Biomedical Journal” Melanocyte stem cells from non-affected skin in vitiligo patients can become functional melanocytes for potential therapy.
April 2024 in “International journal of molecular sciences” Alopecia areata and vitiligo share immune system dysfunction but differ in specific immune responses and affected areas.
April 2024 in “Indian Journal of Paediatric Dermatology” Congenital triangular alopecia and vitiligo can occur together, but treatment for one may not affect the other.
March 2024 in “International journal of molecular sciences” taVNS reduces vitiligo symptoms in mice.
February 2024 in “International Journal of Research in Dermatology” Thyroid tests may not be needed for all vitiligo and alopecia areata patients unless thyroid disease symptoms appear.
Donor lymphocyte infusions effectively treated leukemia relapse but caused vitiligo and alopecia areata.